Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.

ABSTRACT: Multi-factorial diseases are illnesses that exploit multiple cellular processes, or stages within one process, and thus highly targeted therapies often succumb to the disease, losing efficacy as resistance sets in. Combination therapies have become a mainstay to battle these diseases, however these regimens are plagued with caveats. An emerging avenue to treat multi-factorial diseases is polypharmacology, wherein a single drug is rationally designed to bind multiple targets, and is widely touted to be superior to combination therapy by inherently addressing the latter's shortcomings, which include poor patient compliance, narrow therapeutic windows and spiraling healthcare costs. Through its roles in intracellular trafficking, cell motility, mitosis, protein folding and as a back-up to the

SUBMITTER: Chan AM 

PROVIDER: S-EPMC8127619 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature